Evidence map›Paper›PMID 26237203›Full record

ArticleACS applied materials & interfaces2015

Terminal PEGylated DNA-Gold Nanoparticle Conjugates Offering High Resistance to Nuclease Degradation and Efficient Intracellular Delivery of DNA Binding Agents.

Lei Song, Yuan Guo, Deborah Roebuck, Chun Chen, Min Yang, Zhongqiang Yang, Sreejesh Sreedharan, Caroline Glover, Jim A Thomas, Dongsheng Liu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Accumulation ofNanotheranostics · 2017
    Article
  10. Article
  11. Controlling DNA-nanoparticle serum interactions.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lei SongSchool of Chemistry and Astbury Structure for Molecular Biology, University of Leeds , Leeds LS2 9JT, U.K.
Yuan GuoSchool of Chemistry and Astbury Structure for Molecular Biology, University of Leeds , Leeds LS2 9JT, U.K.
Deborah RoebuckDepartment of Chemical Engineering, Imperial College London , South Kensington Campus, London SW7 2AZ, U.K.
Chun ChenDepartment of Chemistry, Tsinghua University , Beijing 100084, P. R. China.
Min YangUCL School of Pharmacy, University College London , 29-39 Brunswick Square, London WC1N 1AX, U.K.
Zhongqiang YangDepartment of Chemistry, Tsinghua University , Beijing 100084, P. R. China.
Sreejesh SreedharanDepartment of Chemistry, University of Sheffield , Sheffield S3 7HF, U.K.
Caroline GloverDepartment of Chemistry, University of Sheffield , Sheffield S3 7HF, U.K.
Jim A ThomasDepartment of Chemistry, University of Sheffield , Sheffield S3 7HF, U.K.
Dongsheng LiuDepartment of Chemistry, Tsinghua University , Beijing 100084, P. R. China.
Shengrong GuoSchool of Chemistry and Astbury Structure for Molecular Biology, University of Leeds , Leeds LS2 9JT, U.K.
Rongjun ChenDepartment of Chemical Engineering, Imperial College London , South Kensington Campus, London SW7 2AZ, U.K.
Dejian ZhouSchool of Chemistry and Astbury Structure for Molecular Biology, University of Leeds , Leeds LS2 9JT, U.K.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Over the past 10 years, polyvalent DNA-gold nanoparticle (DNA-GNP) conjugate has been demonstrated as an efficient, universal nanocarrier for drug and gene delivery with high uptake by over 50 different types of primary and cancer cell lines. A barrier limiting its in vivo effectiveness is limited resistance to nuclease degradation and nonspecific interaction with blood serum contents. Herein we show that terminal PEGylation of the complementary DNA strand hybridized to a polyvalent DNA-GNP conjugate can eliminate nonspecific adsorption of serum proteins and greatly increases its resistance against DNase I-based degradation. The PEGylated DNA-GNP conjugate still retains a high cell uptake property, making it an attractive intracellular delivery nanocarrier for DNA binding reagents. We show that it can be used for successful intracellular delivery of doxorubicin, a widely used clinical cancer chemotherapeutic drug. Moreover, it can be used for efficient delivery of some cell-membrane-impermeable reagents such as propidium iodide (a DNA intercalating fluorescent dye currently limited to the use of staining dead cells only) and a diruthenium complex (a DNA groove binder), for successful staining of live cells.

Indexed as

Antibiotics, AntineoplasticCell SurvivalCoordination ComplexesDeoxyribonuclease IDNADoxorubicinDrug CarriersDynamic Light ScatteringGoldHeLa CellsHumansIntercalating AgentsMetal NanoparticlesMicroscopy, ConfocalPolyethylene GlycolsPropidiumAntibiotics, AntineoplasticCoordination ComplexesDeoxyribonuclease IDNADoxorubicinDrug CarriersGoldIntercalating AgentsPolyethylene GlycolsPropidiumRutheniumDNA−gold nanoparticle conjugateDNA intercalation reagentDNase resistancedrug deliveryPEGylation

Identifiers

PMID26237203
PMCPMC4554298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.